Johns Hopkins Hospital

Baltimore, MD


The Pediatric Neuro-Oncology (PNO) Program at Johns Hopkins is part of the Division of Pediatric Oncology within the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.  National Cancer Institute designation as a Comprehensive Cancer Center is the gold standard for cancer hospitals, and Johns Hopkins is the only one that has earned this designation in Maryland.  Care for children and young adults with brain and spinal cord tumors is coordinated through a multidisciplinary team of providers who focus their basic, translational and clinical research exclusively on pediatric brain tumors. Pediatric Oncology is located in the new $1.3 billion, 12-story Charlotte R. Bloomberg Children’s Center building, one of the most technologically advanced and comprehensive children’s hospitals in the world. The pediatric oncology unit has separate but adjacent inpatient and outpatient units designed to provide seamless continuity of care for all patients.

Advances have been built on the discoveries of Johns Hopkins scientists including deciphering the genome of more cancer types than any other research team in the world and doing much of the preclinical and translational work for the development of immune-oncology and epigenetic therapies. These discoveries have been used to revolutionize pediatric cancer care through targeted and individualized diagnostics and therapeutics. These kinds of scientific advances define Johns Hopkins, but the facilities that allow us to deliver this care in a welcoming and family friendly environment also make us unique.

Housing Information

Visit the Johns Hopkins Hospital website for more information on housing.

Contact information


Pediatric Neuro-Oncology
1800 Orleans St., Bloomberg 11379
Baltimore, MD  21287

Phone:  410-614-5055
Fax:  410-955-0028


Principal Investigator
Director of Pediatric Neuro-Oncology and Clinical Director of the Division of Pediatric Oncology
Dr. Cohen is Director of Pediatric Neuro-Oncology and Clinical Director of the Division of Pediatric Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The Pediatric Neuro-Oncology program at Hopkins conducts a broad range of research centered primarily around the development and testing of new therapies for children with brain tumors. Recent research has focused on the most high-risk brain tumors, including the use of molecularly targeted therapies and novel delivery systems. The multidisciplinary nature of this work translates into continual collaboration with specialists in pediatric neurosurgery, radiation oncology, neuropathology, neuroradiology, neurology, neuro-ophthalmology, and neuropsychology. As Clinical Director of the Pediatric Oncology Division, Dr. Cohen is responsible for the operation of all of the division’s inpatient and outpatient services. In addition, he oversees the full range of clinical trials under way throughout the division. Dr. Cohen is co-chair of the High-Grade Glioma Committee for the Children's Oncology Group. He is a lead author for the PDQ® Cancer Information - National Cancer Institute brain tumor treatment summaries. He is on the scientific advisory for the St. Baldrick’s Foundation. He also serves on the scientific advisory boards of the Childhood Brain Tumor Foundation and Curing Kids Cancer. He is the Chair of the Johns Hopkins Institutional Review Board #6.
Co-Principal Investigator
Assistant Professor of Oncology
Dr. Eric Raabe is assistant professor of Pediatric Oncology at Johns Hopkins. In addition to caring for pediatric brain tumor patients, Dr. Raabe's research focuses on translational neuro-oncology, with the overall goal being to develop new therapeutics for poor-prognosis brain tumors. He has significant expertise in stem cell biology, developmental biology and murine xenografting. He has developed normal human neural stem cells for use as genetically accurate gain-of-function models for high-risk brain tumors, including models of high and low grade glioma, medulloblastoma, as well as DIPG. Dr. Raabe's lab group has provided the preclinical data supporting numerous current or planned national pediatric brain tumor clinical trials in tumors including DIPG, low-grade glioma and medulloblastoma.